Anyone researching ingredients in topical skin creams may come across palmitoyl tripeptide-1 on a product label. Here is what the available labeling and trial data actually say about it.
Key takeaways
- Palmitoyl tripeptide-1 is formulated as a topical cream product, marketed under the brand name BUDDATE REGES INTENSIVE TREATMENT.
- The product label describes it as a cream applied to the skin, without listing a pharmacologic class or mechanism of action.
- One registered trial references palmitoyl tripeptide-1, an AI-personalized skincare regimen study for facial photoaging, which has completed.
- No boxed warning is associated with this product's labeling.
- No adverse event reports were identified in the data reviewed.
What Palmitoyl Tripeptide-1 Is
Palmitoyl tripeptide-1 is a compound (PubChem CID 10231864) formulated into a topical cream intended for application to the skin. The available labeling does not specify a drug class or describe a mechanism of action.
What Palmitoyl Tripeptide-1 Is Approved For
Labeling for the brand BUDDATE REGES INTENSIVE TREATMENT describes it as a cream meant to be applied to areas of the body needing nourishment, massaged gently into the skin. The label does not describe a boxed warning for this product.
What the Evidence Shows
One trial in the registry involves palmitoyl tripeptide-1. That study, an AI-personalized skincare regimen for facial photoaging in women, has reached completed status. The trial registry does not list a development phase for this study.
Reported Side Effects
No adverse event reports for palmitoyl tripeptide-1 were found in the data reviewed. This does not necessarily mean no side effects occur, only that none appear in the dataset examined.